Ovid Therapeutics Inc.
NCM: OVIDLive Quote
📈 ZcoreAI Score
Our AI model analyzes Ovid Therapeutics Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get OVID Z-Score →About Ovid Therapeutics Inc.
Healthcare
Biotechnology
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia. It has license and collaboration agreements with AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
📊 Fundamental Analysis
Ovid Therapeutics Inc. demonstrates a profit margin of -240.1%, which is below the sector average, suggesting competitive pressure.
The company recently reported 844.7% revenue growth, which is well above average for the Healthcare sector.
Return on Equity (ROE) is -17.5%, which indicates that capital utilization is currently under pressure.
At a current price of $2.75, OVID currently trades near the top of its 52-week range (88%) (Range: $0.26 - $3.10).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
✅
Revenue Growth
Excellent
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$415.33M
Trailing P/E
--
Forward P/E
-5.87
Beta (5Y)
-0.03
52W High
$3.10
52W Low
$0.26
Avg Volume
2.90M
Day High
Day Low